Auromedics Pharma

Eugia US is excited to welcome Krishna Patel, Associate, QA Product Complaint & Recall. Krishna is an experienced healthcare professional with more than 10 years of experience as Drug Safety Associate, Pharmacology Associate, Quality Chemist and Pharmacy Technician. Over the years, she has been successful in processing ICSR for Product Complaints, serious adverse events (SAE) …

Eugia US is pleased to welcome David Anderson, Strategic Account Manager. David resides in Phoenix, Arizona. He has over 15 years of experience selling pharmaceuticals (Generic Injectables, Biosimilars and 503B) specializing in IDNs and National Accounts. We are thrilled to have David on our team and bring his generic injectable expertise along with his customer relationships to grow …

Eugia US is pleased to welcome Kim Stahl, our newest Territory Business Manager covering Texas and Oklahoma. Kim resides in Katy, TX, with her four children. She has been in the pharmaceutical industry for 15 years, specializing in oncology, generic injectables, GPO Knowledge, and handling large IDNs. Prior to Eugia, she worked for Fresenius-Kabi, which awarded …

Eugia US is pleased to welcome Michael Tedesco, Business Analytics and Insights. Michael lives with his wife in Morristown, New Jersey. He has been in the pharmaceutical industry for 20 years holding multiple roles in commercial analytics, sales operations, data analysis, and portfolio management. Prior to Eugia, he has worked for IQVIA, Sandoz, Mylan, and Johnson & Johnson. …

Visit Eugia at National Pharmacy Purchasing Association’s (NPPA) annual meeting, August 14-17, 2023 at Horseshoe Las Vegas. Eugia will be in Booth 213 and will be highlighting several important New Product Launches: Bendamustine, Diltiazem, Methylprednisolone (MDV), Tirofiban, Carboprost, Plerixafor, and Vancomycin. Additionally, company leadership will be present to meet customers and answer questions including:

Eugia US is pleased to announce the newest launch of Vancomycin Hydrochloride for Injection USP, 1.25 g/vial and 1.5 g/vial, Single Dose Vial. Indicated in adults and pediatric patients (neonates and older) for the treatment of: This New Product Launch demonstrates our commitment to meet our customer needs by providing high-quality products, flexible pricing, and consistent …

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Carboprost Tromethamine Injection USP 250 mcg/mL, Single-Dose Vials. Indications for this product include: Carboprost tromethamine injection is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not …

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) [Single-Dose Flexible Container] Indications for this product include: Refer to package insert for full prescribing information.

Eugia US LLC has initiated a voluntary recall of lot number CPB200013 of Acyclovir Sodium Injection 500 mg/10 mL (50 mg/mL), due to the presence of particulate matter.

Eugia Pharma Limited has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial and 150 mg/mL, 1 mL Prefilled Syringe.

Eugia US has transitioned to a new specialty business called Eugia, under the parent company Eugia Pharma Specialties Limited. The new name reflects a focus on quality and service.

Eugia US has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Vasopressin Injection USP, 20 units/‌mL, 1 mL MDV. Indications include increasing blood pressure in adults with vasodilatory shock.

Eugia US has received tentative approval from the US Food & Drug Administration (USFDA) for Plerixafor Injection 24 mg/1.2 mL, indicated for mobilizing hematopoietic stem cells for collection.

Eugia US LLC has initiated a voluntary recall of Polymyxin B for Injection USP, 500,000 Units/Vial, due to particulate matter.

Eugia Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) for Doxercalciferol Injection 2 mcg/1 mL & 4 mcg/2 mL, indicated for secondary hyperparathyroidism in adult patients with CKD on dialysis.

Eugia US has announced promotions for three sales leaders, including Rob Bloomer, Kyle Grupas, and Katherine Bowman.

Eugia US has received approval from the US FDA for Diltiazem Hydrochloride Injection in various dosages and vial types.

Eugia US has received approval from the US FDA for Hydralazine Hydrochloride Injection USP, 20 mg/mL, Single-Dose Vials.

Eugia US has received approval from the US FDA for Voriconazole for Injection, 200 mg/Vial, Single-Dose Vials.

Eugia US has received approval from the US FDA for Azacitidine for Injection, 100 mg, Single-Dose Vial.

Eugia US has received approval from the US FDA for Amphotericin B Liposome for Injection, 50 mg/vial, Single-Dose Vial.

Eugia US has received approval from the US FDA for Regadenoson Injection, 0.4 mg/5 mL, Indications include myocardial perfusion imaging.

Eugia US LLC has initiated a voluntary recall of Acyclovir Sodium Injection 500 mg/10 mL, due to particulate matter.

Eugia Pharma Limited has received approval from the US FDA for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL, 1 mL Single-Dose Vial and 150 mg/mL, 1 mL Prefilled Syringe.

Eugia US has transitioned to a new specialty business called Eugia, under the parent company Eugia Pharma Specialties Limited. The new name reflects a focus on quality and service.